229
Participants
Start Date
May 30, 2018
Primary Completion Date
February 19, 2025
Study Completion Date
February 19, 2025
Relatlimab
Specified dose on specified days
Nivolumab
Specified dose on specified days
BMS-986205
Specified dose on specified days
Ipilimumab
Specified dose on specified days
Local Institution - 0008, Lausanne
Local Institution - 0012, Wollstonecraft
Local Institution - 0011, Nedlands
Local Institution - 0007, Zurich
Local Institution - 0017, Marseille
Local Institution - 0004, Baltimore
Local Institution - 0021, Madrid
Local Institution - 0018, Madrid
Local Institution - 0022, Málaga
Local Institution - 0020, Pamplona
Local Institution - 0016, Toulouse
Local Institution - 0001, Germantown
Local Institution - 0010, Forlì
Local Institution - 0005, St Louis
Local Institution - 0003, Aurora
Local Institution - 0009, Napoli
Local Institution - 0006, Duarte
Local Institution - 0015, Villejuif
Local Institution - 0023, Rome
Local Institution - 0019, Barcelona
Local Institution - 0013, Headington
Local Institution - 0014, Newcastle upon Tyne
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY